Division of Nephrology, The University of Chicago Medical Center, Chicago, IL 60637, USA.
Medicina (Kaunas). 2021 May 3;57(5):439. doi: 10.3390/medicina57050439.
Kidney transplantation is the best treatment modality for end-stage kidney disease, leading to improvement in a patient's quality and quantity of life. With significant improvements in short-term outcomes, prolonging long-term allograft and patient survival remain ongoing challenges. The ability to monitor allograft function, immune tolerance and predict rejection accurately would enable personalization and better prognostication during post-transplant care. Though kidney biopsy remains the backbone of transplant diagnostics, emerging biomarkers can help detecting kidney allograft injury early enough to prevent permanent damage and detect injury before it is clinically apparent. In this review, we summarize the recent biomarkers that have shown promise in the prediction of acute rejection with a focus on antibody-mediated rejection in kidney transplantation.
肾移植是治疗终末期肾病的最佳方法，可改善患者的生活质量和数量。随着短期结果的显著改善，延长长期移植物和患者的生存仍然是持续存在的挑战。能够准确监测移植物功能、免疫耐受和预测排斥反应将使移植后护理期间的个性化和更好的预后成为可能。虽然肾活检仍然是移植诊断的基础，但新兴的生物标志物可以帮助早期发现肾移植损伤，以防止永久性损伤，并在临床上出现之前检测到损伤。在这篇综述中，我们总结了最近在预测急性排斥反应方面显示出前景的生物标志物，重点是肾移植中的抗体介导的排斥反应。
